# IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB

> **NCT02660346** · PHASE4 · COMPLETED · sponsor: **Sharp HealthCare** · enrollment: 40 (actual)

## Conditions studied

- Bacteremia

## Interventions

- **DRUG:** Daptomycin
- **DRUG:** Vancomycin
- **DRUG:** Ceftaroline

## Key facts

- **NCT ID:** NCT02660346
- **Lead sponsor:** Sharp HealthCare
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2017-09-15
- **Final completion:** 2018-01-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02660346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02660346, "IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02660346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*